New R&D Tax Incentives Enough To Support Korean Drug Development?
This article was originally published in PharmAsia News
Executive Summary
The South Korean government has unveiled more details of new R&D tax support for emerging industries, including bio-health care, to encourage research spending by the pharma sector. But a local industry association suggests the government may also have to think twice about an existing R&D tax incentive system that provides incremental reductions and gives preferential benefits to smaller firms.